PANACENT Trademark

Scientific research services for both medical and non-medical purposes based on transcriptomics, genomic, and proteomic analyses and providing custom consulting services related thereto; Scientific research services for both medical and non-medical purposes, namely analyses and providing custom consulting services based on single-cell omics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Scientific research services for analysis of clinical trial data providing custom consulting services related thereto; Scientific research services for identification of therapeutic target and pathways based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data, and providing custom consulting services related thereto; Software as a service (SaaS) services featuring software for AI-based identification, collection, curation, and presentation of single-cell data from third party sources; Software as a service (SaaS) services featuring software for AI-based training and generation of translational systems biology models using single-cell data from third party sources, and data from bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based integration and analysis of single-cell data from third party sources and clinical data, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based analysis of single-cell omics, proteomics, transcriptomics, and genomics; Software as a service (SaaS) services featuring software for identification of therapeutic and cellular pathway target; Software as a service (SaaS) services featuring software for development of novel therapeutic compounds; Software as a service (SaaS) services featuring software for prediction of drug responses and treatment optimization for individual patients based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data and patient-specific data; Software as a service (SaaS) services featuring software for patient stratification based on disease progression or recurrence risk identifying those who may benefit from more aggressive treatment or monitoring based on molecular single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for matching patients with clinical trials based on single-cell omics, proteomics, genomics transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data